Phaarmasia Limited.

Healthcare · Pharmaceuticals & Biotechnology

BSE: 523620
₹88.00
▼ -1.55 (-1.73%)
Sept. 29, 2026 · BSE · bse_bhavcopy
Quality
68/100
Moderate
Valuation
89/100
Undervalued
Momentum
52/100
Neutral

QVM read Cheap on its own multiples Quality Moderate, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹60 Cr
PE (TTM)
3.7
Industry median 36.1 (152 companies)
Price to Book
2.7
PEG (TTM)
0.0
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
53.7
Free Cash Flow
₹-16 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
25.00%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
1059.59%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
69.67%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-33.90%
as of March 31, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
20.50%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
3.46
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.05
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
87.53
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
-9.09%
as of March 31, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
3.80%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
51.95%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
50.95%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
86.84%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
69.31%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.05)
  • Yes Return on equity is 15% or more (69.3%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

4 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • Yes Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.7%
Low 87.8500 · High 88.0000
1W return
-2.2%
Low 85.5000 · High 90.0000
1M return
-7.9%
Low 81.5500 · High 104.9500
52W return
53.7%
Low 67.0000 · High 104.9500
Lifetime High ₹400.0000 (May 14, 2008)
Lifetime Low ₹6.1800 (April 2, 2014)

Full price history and technicals →

EMA & SMA

Bullish4
Bearish2
5D
88.9
10D
88.6
20D
86.8
50D
76.7
100D
63.8
200D
44.6

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
89.7%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

87.95
Pivot
First resistance88.05
Second resistance88.10
Third resistance88.20
First support87.90
Second support87.80
Third support87.75
Day RSI55.9
Day MFI57.5
Day MACD3.30
Day MACD signal4.20

Beta

1M-0.15
3M0.92
1Y0.92
3Y0.21

Price change analysis

↓ -7.9%
Over 1 Month
LowHigh
81.55104.95
↑ 53.7%
Over 3 Months
LowHigh
67.00104.95
↑ 53.7%
Over 6 Months
LowHigh
67.00104.95
↑ 53.7%
Over 1 Year
LowHigh
67.00104.95
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 3.7 (own history: 2.4–111.4)
Buy Zone
Revenue (June 30, 2026)
₹8 Cr
Net profit (June 30, 2026)
₹— Cr
Basic EPS (June 30, 2026)
₹0.5000

Ranks #148 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter73.51%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 73.51% in Jun 2026 qtr

Historical fii holding

All shareholding details →

Corporate Announcements

All 4 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
29 Sep 2026 AGM/EGM Phaarmasia Ltd - 523620 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
28 Sep 2026 Insider Trading / SAST Phaarmasia Ltd - 523620 - Closure of Trading Window
25 Sep 2026 AGM/EGM Phaarmasia Ltd - 523620 - Shareholder Meeting / Postal Ballot-Outcome of AGM
3 Sep 2026 AGM/EGM Phaarmasia Ltd - 523620 - Intimation Of 45Th Annual General Meeting Of Phaarmasia Limited And Remote E-Voting.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • High Return on Equity (69.3%)
  • Low financial leverage (Debt/Equity 0.05)
  • Comfortable interest coverage (87.5x)
  • Strong revenue growth YoY (20.5%)

Weaknesses

  • Thin net profit margin (-9.1%)
  • Declining profit YoY (-33.9%)

Opportunities

  • PEG below 1 (0.00) -- earnings growth outpacing its own valuation
  • PE below 15 (3.7) relative to a typical growth business

Threats

Data unavailable.

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Phaarmasia Limited.

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.